Bortezomib (BTZ) is a reversible proteasome inhibitor. It affects NF-κB activity and has shown clinical efficacy in multiple myeloma. However, the same mechanisms through which it curtails malignant growth may compromise antitumor immunity. As dendritic cells (DC) play a vital role in the elicitation and maintenance of antitumor immunity, we studied the long-term effects of BTZ on human DC development and function. The CD34 + MUTZ-3 cell line, stably transduced with human telomerase reverse transcriptase (hTERT), was employed as a sustainable model to study human steady-state DC development and was grown in the presence of consecutively rising BTZ concentrations over a period of 4 months. The thus generated BTZ adapted cells were prospectively assessed for their ability to develop into mature Langerhans cells (LC). Long-term exposure to BTZ (>10 months) at a clinically relevant and apoptosis-inducing concentration (10 nM) provoked spontaneous differentiation in surviving precursors, evidenced by increased expression levels of CD14, TNF receptors and immunoproteasome subunits. Cytokine-dependent differentiation was also enhanced, resulting in increased numbers of mature DC with higher levels of co-stimulatory molecules and an increased capacity for T cell induction. Assessment of nuclear NF-κB subunit levels provided evidence for a role of canonical RelB/ p50 activation in the enhanced DC differentiation and maturation established through prolonged BTZ exposure. We conclude that long-term BTZ treatment is compatible with DC-dependent induction of antitumor immunity.
Introduction
The constitutive proteasome is part of the ubiquitin proteasome system (UPS). The constitutive proteasome is responsible for the degradation of cellular proteins and harbors the β5 (PSMB5), β1 (PSMB6) and β2 (PSMB7) subunits, which cleave proteins after hydrophobic, acidic, and basic amino acid residues, respectively. 1 The immunoproteasome consists of the β5i (LMP7), β1i (LMP2), and β2i (MECL1) subunits which are expressed after stimulation with pro-inflammatory cytokines like IFN-γ and TNFα and which replace the corresponding subunits of the constitutive proteasome. 2 As opposed to constitutive proteasomes, which are expressed in most mammalian cells, immunoproteasomes are mainly expressed in cells of hematological origin. Although both types are important in antigen processing, immunoproteasome subunits are able to generate distinct MHC class I epitopes. 3 Proteasomal degradation vitally controls intracellular levels of proteins involved in the regulation of key cellular processes such as differentiation, proliferation, stress, apoptosis, survival, immune activation and antigen presentation. A therapeutic window for proteasome inhibitors as anticancer drugs has been established and attributed to higher expression levels of proteasome subunits, accompanied by increased proteasome activity, in malignant cells. [4] [5] [6] [7] Bortezomib (BTZ) is the first proteasome inhibitor that has shown clinical benefit and is now standard treatment for patients with multiple myeloma (MM) and non-Hodgkin lymphoma. 8, 9 Through a reversible interaction, mediated by a boron group, BTZ is able to inhibit both the constitutive and the immunoproteasome. 10 BTZ treatment of tumor cells leads to accumulation of pro-apoptotic proteins along with decreased levels of anti-apoptotic proteins 11 and interferes with NF-κB activation, which besides apoptosis also controls the expression of growth factors and cytokines important for tumor pathogenesis. 12 BTZ has been reported to induce immunogenic death of tumor cells through exposure of heat shock proteins (HSP60 and HSP90), leading to uptake by and activation of antigen-presenting cells and subsequent activation of anti-tumor effector T cells. 13, 14 As the most powerfully equipped antigen-presenting cells with the unique ability to induce naïve T cell activation and abrogate tumor-imposed immune tolerance, dendritic cells (DC) rely on the UPS for antigen processing. 15 The effects of BTZ on DC have been tested in several preclinical studies with contradictory findings. Most studies have involved in vitro effects on monocyte-derived DC (MoDC) and have shown inhibition of DC development and function. [16] [17] [18] [19] Effects reported have included down-regulation of CD1a, DC-SIGN, HLA-DR and the co-stimulatory molecules CD40, CD80, and CD86. Also, apoptosis was induced by up-regulation of the pro-apoptotic protein Bax. 20 The DC developmental stage appeared to determine susceptibility to BTZ, as mature
MoDC displayed a relative resistance to its inhibitory and pro-apoptotic effects.
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In contrast to these in vitro studies, a recent report showed improved in vivo DC maturation upon BTZ treatment with elevated frequencies of intratumoral DC and the induction of effective T cell-mediated immune protection against tumor outgrowth.
22 Thus far studies have concentrated on short-term exposure (5-7 days) to the drug. However, clinical efficacy requires long-term exposure to BTZ over the course of multiple treatment cycles. 23 Therefore, preclinical evaluation of the long-term effects of BTZ on DC is important, particularly in view of a possible immune component in the efficacy of BTZ 14, 22 and recent surges of interest in combining standard treatment schedules for MM with immunotherapy.
24,25
The detailed preclinical assessment of the long-term effects of drugs on human DC development is hampered by the inability to culture primary DC pro- 
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Over a period exceeding twelve months (>100 passages) MUTZ-3 cells were intermittently exposed to increasing doses of BTZ, leading to low-level resistance and spontaneous early DC differentiation (i.e. independent of differentiation-inducing cytokines). Accordingly, cytokine-induced LC differentiation of these BTZ-adapted precursors was enhanced and marked by higher levels of characteristic lineage and maturation markers and the induction of stronger allogeneic T cell responses. In an attempt to unravel the mechanism underlying these effects, we uncovered evidence for a possible role for BTZ-induced nuclear translocation of RelB/p50 NF-κB complexes. Most importantly, our data support the notion that long-term treatment with BTZ is compatible with the induction of DC-dependent antitumor immunity.
Materials and Methods

hTERTMUTZ-3 progenitor culture and Langerhans Cell cultures
Maintainable MUTZ-3 DC precursors stably expressing human telomerase reverse transcriptase, i.e. the rate-limiting component of the telomerase complex (hereafter referred to as hTERTMUTZ-3), were derived through retroviral transduction of the AML-derived MUTZ-3 cell line, as described previously. 26 Equivalent LC/DC differentiation ability of the parent and hTERT-transduced cell line was demonstrated. 26 hTERTMUTZ-3 progenitor cells were cultured in MEM-α medium (Lonza, Vervier, Belgium) containing 20% fetal calf serum (FCS), 100 IU/ml sodium-penicillin, 100 μg/ml streptomycin, 2 mML-glutamine, 50 μM β-mercaptoethanol, and 10% 5637 (renal cell carcinoma) conditioned medium (MUTZ-3 routine culture medium) in T75 (BD Falcon) at a concentration of 0.2×10 6 cells/ml and were passaged twice weekly.
LC were cultured from hTERTMUTZ-3 progenitors with 10 ng/ml TGFβ (Biovision, Mountain View, CA), 1,000 IU/ml rhGM-CSF (Sagramostim, Berlex), and 125 IU/ml TNFα (Miltenyi Biotec, Bergisch Gladbach, Germany) for 9 days to obtain immature MUTZ3-LC as described previously. 27 To study short term effects of BTZ on MUTZ3-LC differentiation, BTZ (5 nM) was added to hTERTMUTZ-3 progenitors (i.e. BTZ unexposed) at the start of differentiation. Immature MUTZ3-LC were further matured by adding monocyte condition medium (MCM)-mimic consisting of 100 ng/ml IL-6 (R&D Systems, Abingdon, England), 1 µg/ml prostaglandin-E2 (PGE2) (Sigma-Aldrich, Zwijndrecht, The Netherlands), 25 ng/ml IL-1β (Miltenyi Biotec, Bergisch Gladbach, Germany) and 2,400 IU/ml TNFα for 48 h.
Short-and long-term culture with bortezomib
Bortezomib (BTZ)/Velcade was provided by Millennium Pharmaceuticals (Cambridge, USA).
The bortezomib adaptation of hTERTMUTZ-3/10BTZ precursors was acquired by long-term exposure of hTERTMUTZ-3 progenitors to the drug. Starting concentration (at passage 22) was 2 nM BTZ and was increased to 8 nM (passage 38) and 10 nM (passage 51). Both increases occurred after approximately 1 month.
From passage 51 the drug was added intermittently (on and off every 2 passag-es). Of note, all analyses and experiments using the hTERT-MUTZ3/10BTZ were performed after the cells were exposed to the drug for at least one passage. Proteasome Constitutive-Immuno Subunit ELISA assay (ProCISE)
FACS analysis -immunophenotyping
The ProCISE assay for quantification of individual constitutive ( β5, β1, β2) and immunoproteasome ( β5i, β1i, β2i) subunits was performed as previously described. 
Mixed leukocyte reaction (MLR)
hTERTMUTZ - 
Analysis of NF-κB subunit activation
hTERTMUTZ-3 and hTERTMUTZ-3/10BTZ precursor cells were either not stimulated (CTR) or stimulated with TGFβ (10 ng/mL), rhGM-CSF (1000 IU/ mL) and TNFα (120 IU/mL) for one hour. Immature LCs were incubated with maturation cytokines (MCM-mimic) for one hour. Nuclear pellets were made using Nucbuster protein extraction kit (EMD Millipore, Massachusetts, USA) according to the manufactures' protocol. Activation of p50, p52, RelB, or RelA/ p65 was determined using the TransAM NF-κB Family kit (Active Motif Europe, Rixensart, Belgium) according to the manufacturer's instructions.
Statistical analysis
For comparisons between groups, ANOVA or Student's t-test was used.
Differences were considered to be significant when p < 0.05. These tests as well as linear regression analysis and plotting of 90% prediction band with the Pamchip data was carried out using GraphPad Prism software, version 5.01.
Results
Long-term culture with BTZ induces "BTZ adaptation" in hTERT-MUTZ-3 progenitor cells
To study the long term effects of BTZ on human DC development, hTERT-MUTZ-3DC progenitor cells were cultured in the presence of BTZ, starting at a concentration of 2 nM (from passage 22) and the concentration was gradually 
Long-term culture with BTZ induces differentiation of hTERT-MUTZ-3 progenitor cells
MUTZ-3 consists of a predominant CD34
+ proliferative fraction and a small (typically less than 10%) population of CD14 + precursor cells, arising from CD34 + precursors, with the ability to rapidly differentiate to DC. 28 Over the course of long-term BTZ exposure CD14 expression was assessed (passages: 58, 62, 85
and 95, see Figure 1C ) and were consistently found to hTERTMUTZ-3/10BTZ
as compared to unexposed progenitor cells, indicative of enhanced early differentiation events. Next, we also determined the expression of cytokine receptors involved in DC differentiation (TNF-RI and -RII) and DC precursor proliferation (cKIT/CD117 and IL-3R/CD123), 31, 32 under normal conditions or BTZ exposure at 10 nM, between passages 58 and 95. As shown in Figure 1D , consistent and selective up-regulation of TNF-RI and -RII, both previously associated with DC differentiation ability, 31 was in keeping with the observed increased differentiation propensity. Also an increase in immunoproteasome subunit content was observed, consistent with an elevated differentiation state, 33, 34 see Figure 1E . The immature LC arising in the different conditions were subsequently tested for their ability to mature in response to a cytokine cocktail consisting of IL-6, PGE2, IL-1β and TNFα (see "Materials and Methods"). Figure 3A is representative of at least five separate experiments and shows consistently enhanced 
. Long-term, not short-term, exposure to Bortezomib (BTZ) enhances the differentiation of Langerhans Cells (LC). (A) Langerin + and CD1a + LC, differentiated from hTERT-MUTZ-3, hTERTMUTZ-3 in the presence of 5 nM BTZ and BTZ-adapted hTERTMUTZ-3/10BTZ cells. Data are representative for 10-15 separate experiments. (B) Expression of CD34, CD14, and CD1a on LC in percentage positive cells (mean ± SD of 10-15 separate experiments). (C) Expression of T cell (co-)stimulatory molecules CD80, CD86, CD40, HLA-ABC and HLA-DR on LC differentiated in the absence or presence of BTZ (5 nM) or differentiated from MUTZ-3 precursors upon their long-term exposure to BTZ (hTERTMUTZ-3/10BTZ). Results are representative of 10-15 separate experiments. (D) Expression on LC of CD80 and CD86, CD40 and HLA-ABC and HLA-DR in Mean Fluorescence Index (MFI) as mean ± SD of 10-15 separate experiments for the indicated conditions.
up-regulation of all tested maturation markers, i.e. CD83, CD80, CD86, CD40, HLA-DR and HLA-ABC. A crucial function of mature LC is the induction of naive T cell activation. Consistent with their increased maturation state, mature LC derived from BTZ-adapted precursors induced higher proliferation rates in naïve allogeneic T cells ( Figure 3B ).
Altered tyrosine kinase profile and NF-κB signaling in LC derived from BTZ adapted precursors
To further elucidate sub-cellular changes accompanying the enhanced LC development from long-term BTZ exposed precursors, we evaluated their tyrosine kinase activity profile employing the Tyrosine Kinase PamChip microarray.
Lysates were tested from hTERTMUTZ-3 and hTERTMUTZ-3/10BTZ precursors that remained unstimulated or were stimulated for one hour by the LC differentiation inducing cytokine cocktail. Figure 4A shows the ratios of stimu- 1β, TNFα, IL-6 and PGE2). Elevated levels of the canonical RelA (p65) and p50 subunits in LC derived from the BTZ adapted precursors were observed both before and after ( Figure 4B ) maturation induction. Most notably, RelB activation was induced in the LC from BTZ adapted precursors and virtually absent in their BTZ unexposed counterparts. Although this BTZ-induced up-regulation of nuclear RelB levels did not reach significance due to variability, in all three independent experiments this increase was observed, varying from 2.6-to 20.6-fold. Remarkably, activation of RelB's non-canonical binding partner p52 was not observed under any of the tested conditions ( Figure 4B and C) . These data indicate that beside nuclear translocation of the canonical RelA/p50 dimer, translocation of non-classical RelB/p50dimers in the BTZ-adapted precursors may account for the observed enhanced LC maturation.
APA= Aminopeptidase A, EPHA= Ephrin Type-A Receptor. (B) NF-κB activation was measured in nuclear pellets of LC differentiated from hTERTMUTZ-3(open bars) and BTZ-adapted hTERT-MUTZ-3/10BTZ (closed bars). LC were either left unstimulated or stimulated for one hour with a
Discussion
BTZ treatment can lead to immunogenic cell death in MM cells, resulting in uptake by and contact dependent activation of DC through exposure of heat shock proteins. 13, 14 Given that BTZ can enhance the efficacy of tumor vaccination, 13, 14, 39 these findings have prompted several groups to study the effects of BTZ on functional DC development and maturation. So far a majority of reports have Long-term exposure to BTZ was found to induce an adapted cellular state in hTERTMUTZ-3 progenitor cells, which facilitated a relative resistance to apoptosis induction and was accompanied by spontaneous early differentiation events and enhanced development and maturation of LC, with an increased ability to prime allogeneic T cells. The observed selective BTZ-induced increase in immunoproteasome subunits was consistent with this enhanced DC differentiation and maturation capacity 33, 34, 42 as was the significant up-regulation of both TNF-RI and -RII levels on the BTZ-adapted progenitors. 28, 31 In particular TNF-RI was previously shown to be essential for DC maturation and subsequent CD8 + T cell activation. 43 Of note, TNF-RI signaling involves the NF-κB canonical pathway and is controlled at virtually all levels by ubiquitination and de-ubiquitination events. 44 It therefore stands to reason that proteasome inhibition would induce molecular modulation of TNF-RI-mediated canonical NF-κB signaling and thus affect DC development. BTZ adaptation may thus lead to favoring of the non-canonical RelB-mediated pathway as was reported in BTZ-treated Head and Neck squamous cell tumors, which might possibly account for the heterogeneous response to BTZ in patients with this tumor type. 45 In DC this phenomenon may be reflected by increased signaling through TNF-RII (up-regulated to higher levels on hTERTMUTZ-3/10BTZ), which involves signaling through the non-canonical RelB pathway. 46 However, our finding of nuclear RelB in the absence of p52 is evidence for an alternative scenario in which RelB dimerizes with p50 for nuclear translocation. High levels of RelB is a characteristic of cells belonging to the DC lineage and may account for the recent observation of nuclear translocation of RelB/p50 dimers, thus combining canonical and non-canonical signaling elements in a molecular event that appears to be unique to DC activation. 47 47 Similarly, we found very little difference in tyrosine kinase activity profiles between unexposed and long-term BTZ exposed MUTZ-3 precursors. In both, up-regulation of STAT kinase activity was observed upon differentiation induction (STAT3, STAT5, and STAT6-see Figure 4A ), in keeping with the control of DC development by JAK/STAT signaling networks, irrespective of their regulation by nuclear RelA/p50 or RelB/ p50 complexes. In particular STAT3 and STAT5 activation have previously been implicated in steady-state DC differentiation and maturation from CD34 + precursors. 35, 36, 58 Based on previous reports, some of the rare kinase activities we observed to be differentially regulated between unexposed and BTZ-exposed precursor cells, may actually signal functional differences. For instance, relatively lower induction of tyrosine kinase activity of the Ephrin Type-A receptor 2 in BTZ-exposed precursors may have contributed to the increased capacity of the resulting LC to stimulate naïve T cells. 37 Reciprocally, higher kinase activity of Peripherin, a neuronal intermediate filament protein, 38 in BTZ adapted cells may be associated with a more dendritic morphology, consistent with enhanced LC development. Rather than inducing major shifts in signaling programs and gene expression profiles, it was suggested that RelB/p50 dimers might be subject to different (in)activation mechanisms, leading to their preferred or prolonged activation and thus resulting in superior DC development and maturation.
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Inhibitory effects of BTZ on human DC differentiation and maturation from previously unexposed precursors, as reported by others for MoDC, 16, [18] [19] [20] were not observed in our model, and emphasizes differential effects on human DC development under inflammatory versus steady-state conditions. Thus, our 
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